Viswanath Pilla
moneycontrol
Mumbai, MH, India
Contact Viswanath
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Viswanath:
IPO-bound PharmEasy Parent Appoints Five Independent Directors, To Hire Over 200 Engineers
“The fresh appointments bring a great amount of cognitive diversity to the board, with luminaries from the world of public service, technology, pharma, medical fraternity, and the consumer sector," the company said in a statement. → Read More
Pharma Wrap: COVID-19 Vaccines In Private Market May Cost Rs 900-1,500 Per Dose
Many states have already said they will offer COVID-19 free of cost to their citizens. → Read More
World May See 18 Percent Shortfall In Supply Of COVID-19 Vaccines In 2021: Report
Airfinity pegs the global demand for COVID-19 vaccines in 2021 at 11.5 billion doses, while the forecasted production is estimated to be 9.5 billion doses. → Read More
DCGI Drops 'clinical Trial Mode' Condition For Bharat Biotech's Covaxin
Currently, those receiving Bharat Biotech’s Covaxin are asked to sign a consent form before being vaccinated. → Read More
Bharat Biotech's Covaxin Found To Be Safe, Induced Immune Response In Phase-1
The overall incidence of 'adverse events' was 14–21 percent in all vaccine-treated groups, says the data published in Lancet. The company says the incidence of adverse events are noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates. → Read More
India To Immunise 300 Million People With COVID-19 Vaccine In The Initial Phase, Says NITI Aayog's Vinod Paul
Paul said the safety and immunogenicity data alone will drive the emergency use approvals. The drug regulator has been “insulated” from any interference from the government. → Read More
COVID-19 vaccine | Serum Institute to apply for emergency licence for Covishield vaccine in next 2 weeks
Adar Poonawalla said Serum Institute of India is manufacturing 50-60 million doses of Covishield per month, and from January it would increase the production to 100 million doses per month → Read More
Cyber attack that led to pause in worldwide operations was ransomware, investigation continues: Dr Reddy's
In a ransomware attack, the hackers breach the systems, install malware that encrypts a victim's files, then demand a ransom from the victim to restore access to the data. → Read More
Biocon Biologics bets on insulin glargine ramp-up as it looks overcome a tepid Q2
Despite the operational challenges posed by Covid-19, Biocon’s biologics division says it is committed to achieve its $1 billion revenue target by the end of FY22. → Read More
Pharma wrap: Why India needs to invest more on mental health
The spending on the mental health component is only 0.05 percent of its health budget, lower than even the average spending of many low-income countries. → Read More
Pharma wrap: Festivals, winter perfect setting for Covid surge, can't afford to let the guard down
With a vaccine at least three months away, it becomes important for governments to manage the infection rates but it won't be easy. → Read More
Pharma wrap: 72% Indian doctors see technology critical for cardiac care, Abbott’s latest study says
According to the study, the estimate of age-standardised cardiovascular disease death rate is higher than the global average. → Read More
Pharma wrap: How PM Modi’s National Digital Health Mission can reduce overall health expenses
Experts say, apart from convenience for the patient, or not storing and carrying the health records physically, if implemented well, it can reduce overall healthcare expenses. → Read More
5-day coronavirus treatment to cost no more than Rs 30,000: Hetero
Cipla has not disclosed the pricing of the drug, Hetero said it will supply its version of remdesivir at Rs 5,000- Rs 6,000 per vial. → Read More
CDSCO reviewing Remdesivir applications on priority basis
"Being an injectable formulation, testing for assay, identity, impurities, bacterial endotoxin test and sterility become very critical for patient safety and this data need to be provided by the companies," it added. → Read More
GSK is world's largest vaccine maker. Yet it has been tame with its COVID-19 strategy
GSK is betting on its adjuvant technology to support companies developing COVID-19 vaccines. → Read More
Healthtech startup HealthPlix raises $6 million from JSW Ventures, others
The startup enabled more than 5,000 doctors in digitising their entire clinical operations and clinical treatment methodologies → Read More
Pharma wrap: Govt to give Rs 14k crore boost to promote production of bulk drugs, medical devices
In FY19, India imported about $4.5 billion worth of drug raw materials from China. This equates to about 70-80 percent of our requirement. It also imported almost $6 billion worth of medical devices, which translates to about 80-90 percent of India's needs. → Read More
E-cigarettes banned: What led government to terminate ENDS?
The ordinance proposes maximum imprisonment of up to one year along with a fine of Rs 1 lakh for first-time violators, and imprisonment of upto 3 yrs & fine upto Rs 5 lakh for subsequent offences. → Read More
CG Power sacks CFO, posts Rs 507 crore loss in FY19
Venkatesh was the second head to roll out from the scam-ridden company. → Read More